Lupin Q1 results: Net profit jumps 5-fold to Rs 542 crore

The significant jump in June quarter net profit was on account of robust sales and income received from biopharmaceutical firm Boehringer Ingelheim for achieving key milestones for its novel MEK inhibitor compound collaboration.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news